Using a genetically engineered mouse model we found that an effective immunotherapy with adoptively transferred T cells (pmel-1 T cells) directed against the melanocytic target antigen gp100 (also known as Pmel) caused regressions of established melanomas but tumours invariably recurred. This evidence concerns the gene PMEL and melanoma.